Overview

Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. The Company granted to Biogen an irrevocable license to all of its IP through the recent License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 opposition proceeding.


Most Recent Presentation
Download Documentation September 2017 Presentation

Stock Information
FWP (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$5.69
Change (%) Stock is Down 0.11 (1.90%)
Volume12,689
Data as of 09/25/17 12:21 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: FWP.OQ.  Currently trading at $5.69 with a 52 week high of $9.67 and a 52 week low of $2.70.

Recent NewsMore >>
DateTitle 
09/05/17Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit
COPENHAGEN, Denmark, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing in the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) of the opening brief for the appeal of the PTAB decision that ended the interference proceeding between the Forward 11/576,871 patent application (the “’871 application”) and an issued Biogen patent. “We continue to believe that our intellectual property is strong and that ... 
Printer Friendly Version
09/01/17Forward Pharma Board of Directors Approves Capital Reduction and Returns EUR 917.7 Million to Shareholders
COPENHAGEN, Denmark, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced the final approval by the Company’s board of directors of the plans to return a total of EUR 917.7 million to its shareholders through a capital reduction (the “Capital Reduction”). On September 1, 2017, following this approval, the Company effected the Capital Reduction with a distribution of proceeds to holders of ordinary shares. The record date for holders... 
Printer Friendly Version
08/02/17Forward Pharma Obtains Shareholder Approval of the Planned Capital Reduction at the Extraordinary General Meeting
COPENHAGEN, Denmark, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced the result of the extraordinary general meeting of its shareholders held on August 2, 2017 (the “Extraordinary General Meeting”), where the requisite majority of the votes cast approved the plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction (the “Capital Reduction”). Forward has received... 
Printer Friendly Version
07/18/17Forward Pharma announces planned distribution of EUR 19.45 per share to Shareholders
COPENHAGEN, Denmark, July 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction. This decision is based on a careful evaluation of the most appropriate capital allocation strategy after receipt of the non-refundable USD 1.25 billion cash fee from Biogen. The capital reduction aligns the amount of working capital with t... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources